Trinity Capital Inc. (NASDAQ: TRIN) Sees Positive Outlook from UBS with a $17 Price Target

Core Viewpoint - Trinity Capital Inc. (NASDAQ: TRIN) is positioned for potential growth, with UBS setting a price target of $17, indicating a 14.17% upside from its current price of $14.89 [1][5]. Investment Activity - TRIN has invested $130 million in Candel Therapeutics, a biopharmaceutical company focused on cancer-fighting viral immunotherapies, which may enhance TRIN's portfolio and future earnings [2][5]. Stock Performance - TRIN's stock is currently priced at $14.98, reflecting a slight increase of 1.01% with a price change of $0.15, and has shown volatility with a trading range between $14.72 and $15.015 today [3][5]. - Over the past year, TRIN's stock has fluctuated between a low of $12.50 and a high of $16.82 [3]. Market Metrics - TRIN's market capitalization is approximately $1.05 billion, indicating its size and market presence [4]. - The stock has a trading volume of 365,074 shares, demonstrating active investor interest which can influence price movements [4][5].